ÌÇÐÄVlog

Skip to Content on ¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ·.org
You're location is
All Regions
¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ·r

Nationally Recognized Pediatric Care

Our hospitals are ranked by U.S. News & World Report as among the best in the nation in multi-specialties.

Find Out Why!
Closeup of a person holding a phone using the ¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ· app.

We Make Health Care Easy With the ¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ· App

Access communications, appointment and symptom tracking and more.

Online Bill Pay

Paying a bill online is easy and secure.

Learn More

Send a Free E-Card

Brighten the day of your loved one staying at one of our hospitals. 

Give It a Try
Young child posing with arms out like he is flying.

KidsHealth Library

Healthy living for parents, kids and teens.

Meet Our Team

Learn more about our physician researchers, clinicians and scientists.

Find a Researcher

Refer a Patient

Use ¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ·Link to make a fast, online referral.

Get Access
# #

    Emi H. Caywood, MD

    Physician
    Provider Profile

    ¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ· Children's Hospital, Delaware 1600 Rockland Road Wilmington, DE 19803

    Biography

    Emi H. Caywood, MD is the Director of Transplant and Cellular Therapy of the Moseley Foundation Institute for Cancer and Blood Disorders and the Principal Investigator of the ¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ· NCI Community Oncology Research Program. She is an Associate Professor of Clinical Pediatrics at Thomas Jefferson University. Dr. Caywood received her Bachelor of Arts in Biology at Cornell University and her medical doctoral degree at Robert Wood Johnson Medical School, now Rutgers Medical School. She did her pediatric residency at Georgetown University and her post-doctoral training in The Johns Hopkins/National Cancer Institute combined fellowship program. Dr. Caywood is a pediatric hematologist oncologist and has specialized in the field of transplant and cellular therapy. In this field, she has dedicated herself to improving outcomes for patients with cancer and blood disorders. Namely her work has focused on reduced intensity preparative therapy plans, improve diagnostics, and alternative donor transplant to reduce the morbidity and mortality associated with hematopoetic stem cell transplant and make this therapy more widely available, even for those patients without a matched donor. Additionally, Dr. Caywood leads the ¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ· NCI Community Oncology Research Program (¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ·-NCORP) and has the responsibility of developing this NCI community site spanning 5 pediatric oncology sites in Delaware and Florida to improve access to clinical trials focused on cancer prevention, screening, supportive care, symptom management, surveillance, health-related quality of life, and cancer care delivery. Additionally, she directs clinical oncology and transplant research at ¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾Ã¾«Æ· Childrens' Hospital Delaware as the Institutional Principal Investigator for the Children's Oncology Group (COG), Pediatric Immunodeficiency Transplant Consortium (PIDTC), Pediatric Transplant and Cellular Therapy Consortium (PTCTC), North American Pediatric Aplastic Anemia Consortium (NAPAAC), and Sickle Cell Transplant, Advocacy, and Research Consortium (STAR). Dr. Caywood's research goals include improving outcomes for all children affected by cancer and blood disorders by enhancing the understanding of the biologic basis of these diseases, improving therapies, studying curative strategies, and the delivery of such cures from the laboratory to the bedside.

    Fellowship

    • Pediatric Hematology/Oncology - Johns Hopkins University, 2009

    Residency

    • Pediatrics - Georgetown University Hospital (MedStar Health), 2005

    Education

    • MD - University of Medicine and Dentistry of New Jersey, 2002

    Board Certifications

    • American Board of Pediatrics/Hematology-Oncology

    • γδ CD8+ T cells and novel genetic variants in ZAP70 deficiency; Pediatric Allergy and Immunology; (2023).

    • Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium; The Lancet; (2023).

    • Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia; Infection Control & Hospital Epidemiology; (2023).

    • Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias; Blood Advances; (2023).

    • The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions; Journal of Allergy and Clinical Immunology; (2023).

    • Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC; Blood; (2022).

    • Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease; Blood; (2022).

    • A clinician’s guide to HLA matching in allogeneic hematopoietic stem cell transplant; Human Immunology; (2022).

    • Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management after Chemotherapy for Pediatric Acute Myeloid Leukemia; JAMA Network Open; (2021).

    • Immune profile differences between chronic GVHD and late acute GVHD: Results of the ABLE/PBMTC 1202 studies; Blood; (2020).

    • Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey; Frontiers in Immunology; (2020).

    • Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria; Blood; (2019).

    • The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018); Journal of Allergy and Clinical Immunology; (2019).

    • RHEGMATOGENOUS RETINAL DETACHMENT after INTRAARTERIAL CHEMOTHERAPY for RETINOBLASTOMA: The 2016 Founders Award Lecture; Retina; (2017).

    • Unilateral retinoblastoma managed with intravenous chemotherapy versus intra-arterial chemotherapy. Outcomes based on the international classification of retinoblastoma; Asia-Pacific Journal of Ophthalmology; (2016).

    • Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: A case report; Biomarker Research; (2016).

    • Retinoblastoma control with primary intra-arterial chemotherapy: Outcomes before and during the intravitreal chemotherapy era; Journal of Pediatric Ophthalmology and Strabismus; (2016).

    • Challenges in converting Acute Myeloid Leukemia (AML) genomics into AML clinical trials; Journal of Clinical Oncology; (2015).

    • Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: Evidence from four decades of US population data; Cancer Epidemiology; (2015).

    • Intra-arterial chemotherapy for retinoblastoma in 70 eyes: Outcomes based on the international classification of retinoblastoma; Ophthalmology; (2014).

    • Targeted retinoblastoma management: When to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy; Current Opinion in Ophthalmology; (2014).

    • Abnormalities of the large ribosomal subunit protein, rpl35a, in diamond-blaekfan anemia; Blood; (2008).